A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma | BeOne Medicines

A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

Beigene Study ID

BGB-3111-212

ClinicalTrials.gov ID

NCT03332017

EudraCT Number

2017-001552-54

China Drug Trials ID

CTR20220712

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Study Protocol Statistical Analysis Plan